CoronaVac reduces mortality by 97%: study in Uruguay


Credit: Unsplash / CC0 Public Domain

The CoronaVac vaccine reduces coronavirus mortality by 97 percent, according to the first results of the vaccination campaign in Uruguay, which is largely dependent on the Chinese puncture.

In people who had received two doses, it reduced coronavirus infection by 57 percent and intensive care admissions by 95 percent, according to a report by the nation’s health ministry.

Compared to other vaccines in use, there have been few scientific publications on the effectiveness of CoronaVac, produced by the Chinese company Sinovac, and there are divergent results.

However, Coronavac is widely used in China and two dozen other countries.

Chile reported last month that the first results of its vaccination campaign showed that CoronaVac was 67% effective in preventing symptomatic COVID-19 and 80% effective in preventing death.

The results of trials with CoronaVac in Brazil showed a 50 percent effectiveness in preventing symptomatic infection, while Turkish data said it was more than 80 percent effective.

Uruguay, which began vaccination on March 1, has used CoronaVac in more than 80 percent of cases.

He has reserved the Pfizer-BioNTech jab for the elderly, health workers and other people’s illnesses.


The results are based on the results of two weeks after administering two shots to about 862,000 people, more than 712,000 who received CoronaVac and almost 150,000 Pfizer.

The results showed that Pfizer’s shot was 75 percent effective in preventing infection, 99 percent in preventing diseases that needed ICU admissions, and 80 percent in preventing death.

The results of the two vaccines are not directly comparable, as Pfizer recipients in Uruguay fell into higher-risk categories, the ministry said.

Other studies have given much better results to Pfizer.

The largest real-world study conducted by Pfizer in Israel said this month that it provided more than 95% protection against COVID-19.

CoronaVac is a traditional type of , using inactivated viruses to activate immunity, while Pfizer uses RNA messaging technology.

Uruguay, with a population of 3.5 million, has given at least one dose of vaccine to 45.8% of the target population and two doses to 28.29% on May 25, placing it third in the Americas. behind Chile and the United States.

The country has never had a blockade and has had comparatively few cases during the first months of the outbreak, but in recent weeks it has led the world in daily deaths per capita.

The ministry said the results are preliminary and should be interpreted with caution as some data has not yet been processed.

Coronavac, China, with 80% effectiveness in preventing deaths from COVID: results from Chile

© 2021 AFP

Citation: CoronaVac reduces mortality by 97%: Uruguay study (2021, May 28) retrieved May 28, 2021 at .html

This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.

Source link